H295R: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Alter: issue. Add: s2cid. Formatted dashes. | Use this bot. Report bugs. | Suggested by Eastmain | Category:Human cell lines | #UCB_Category 52/91 |
|||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
'''H295R''' (also referred to as NCI-H295R) is an [[Angiotensin|angiotensin-II]]-responsive [[steroid]]-producing [[Adrenal cortex|adrenocortical]] [[cell line]].<ref name="TP-150519-001">{{cite journal |vauthors=Wang T, Rainey WE |title= Human Adrenocortical Carcinoma Cell Lines. |journal= Mol. Cell. Endocrinol. |volume= 351 |issue= 1 |pages= 58–65 |year= 2012 |pmid= 21924324 |doi= 10.1016/j.mce.2011.08.041 |pmc=3288152}}</ref> It was initially isolated in 1980 from a 48-year-old female patient diagnosed with [[adrenocortical carcinoma]].<ref name="TP-150519-001" /><ref name="TP-150519-002">{{cite journal |vauthors=Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV |title= Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. |journal= Cancer Res. |volume= 50 |issue= 17 |pages= 5488–5496 |year= 1990 |pmid= 2386954 |
'''H295R''' (also referred to as NCI-H295R) is an [[Angiotensin|angiotensin-II]]-responsive [[steroid]]-producing [[Adrenal cortex|adrenocortical]] [[cell line]].<ref name="TP-150519-001">{{cite journal |vauthors=Wang T, Rainey WE |title= Human Adrenocortical Carcinoma Cell Lines. |journal= Mol. Cell. Endocrinol. |volume= 351 |issue= 1 |pages= 58–65 |year= 2012 |pmid= 21924324 |doi= 10.1016/j.mce.2011.08.041 |pmc=3288152}}</ref> It was initially isolated in 1980 from a 48-year-old female patient diagnosed with [[adrenocortical carcinoma]].<ref name="TP-150519-001" /><ref name="TP-150519-002">{{cite journal |vauthors=Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV |title= Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. |journal= Cancer Res. |volume= 50 |issue= 17 |pages= 5488–5496 |year= 1990 |pmid= 2386954 |url= http://cancerres.aacrjournals.org/content/50/17/5488.long }}</ref> The initial polyclonal populations of tumor cells obtained from the patients' tumor were cultured and the resultant cell line was called NCI-H295.<ref name="TP-150519-001" /><ref name="TP-150519-002" /> Because of slow growth rates and easy detachment of the original NCI-H295 strains, efforts were made to select a population of cells with better monolayer attachment and more rapid growth.<ref name="TP-150519-001" /> Three strains were developed, based on the serum supplement used for growth, which have been termed H295R-S1, H295R-S2 and H295R-S3.<ref name="TP-150519-001" /><ref name="TP-150519-003">{{cite journal |vauthors=Rainey WE, Saner K, Schimmer BP |title= Adrenocortical cell lines. |journal= Mol. Cell. Endocrinol. |volume= 228 |issue= 1–2 |pages= 23–38 |year= 2004 |pmid= 15541570 |doi= 10.1016/j.mce.2003.12.020 |s2cid= 1628345 }}</ref> All three strains grow as adherent monolayer cultures.<ref name="TP-150519-001" /> |
||
==References== |
==References== |
||
| Line 5: | Line 5: | ||
==External links== |
==External links== |
||
*[https:// |
* [https://www.cellosaurus.org/CVCL_0458 Cellosaurus entry for H295R] |
||
[[Category:Steroid hormones]] |
[[Category:Steroid hormones]] |
||
Latest revision as of 04:10, 24 June 2023
H295R (also referred to as NCI-H295R) is an angiotensin-II-responsive steroid-producing adrenocortical cell line.[1] It was initially isolated in 1980 from a 48-year-old female patient diagnosed with adrenocortical carcinoma.[1][2] The initial polyclonal populations of tumor cells obtained from the patients' tumor were cultured and the resultant cell line was called NCI-H295.[1][2] Because of slow growth rates and easy detachment of the original NCI-H295 strains, efforts were made to select a population of cells with better monolayer attachment and more rapid growth.[1] Three strains were developed, based on the serum supplement used for growth, which have been termed H295R-S1, H295R-S2 and H295R-S3.[1][3] All three strains grow as adherent monolayer cultures.[1]
References[edit]
- ^ a b c d e f Wang T, Rainey WE (2012). "Human Adrenocortical Carcinoma Cell Lines". Mol. Cell. Endocrinol. 351 (1): 58–65. doi:10.1016/j.mce.2011.08.041. PMC 3288152. PMID 21924324.
- ^ a b Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV (1990). "Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis". Cancer Res. 50 (17): 5488–5496. PMID 2386954.
- ^ Rainey WE, Saner K, Schimmer BP (2004). "Adrenocortical cell lines". Mol. Cell. Endocrinol. 228 (1–2): 23–38. doi:10.1016/j.mce.2003.12.020. PMID 15541570. S2CID 1628345.